About the P. vivax information hub
Video on life-changing treatment to cure relapsing P. vivax malaria.
Roll Back Malaria Eastern and Southern Africa NMCP and Partners Meeting
Primaquine prevents Plasmodium vivax malaria relapses, but adherence to the standard 14-day regimen is poor. We aimed to assess the efficacy of a shorter course (7 days) of primaquine for radical cure of vivax malaria.
Tafenoquine for Plasmodium vivax malaria is heralded among the five new developments in the field of tropical medicine in 2018.
This technical brief developed by the World Health Organisation reviews the biological characteristics, geographical distribution and worldwide burden of P. vivax malaria.
This technical brief features discussions on translating guidelines into policy and strategy in programmes for the control and elimination of Plasmodium vivax malaria.
The research investigated the prevalence and characteristics of splenic complications in patients with vivax malaria from 2005 to 2017 in a university hospital.
The objective of this study was to collect data on chloroquine resistance in French Guiana by associating a retrospective evaluation of the therapeutic efficacy and an analysis of recurrent parasitemia from any patients.
Our results indicate that PvRBP2b warrants further preclinical development as a blood-stage vaccine candidate against P. vivax. Total IgG responses to PvRBPs were also shown to be promising immunological markers of exposure to P. vivax infection.
This study demonstrates PvMSP3α antibodies acquired during P. vivax infection can mediate complement-fixation and shows the important influence of age in shaping these specific antibody responses. Further studies are warranted to understand the role of these functional antibodies in protective immunity against P. vivax malaria.